Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosrenol vs Existing Therapy in ESRD Hyperphosphatemia
NCT00160121Phase 4Completed
- Sponsor
- Takeda
- Start
- Jan 2005
- Primary completion
- Dec 2005
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of lanthanum carbonate in hyperphosphatemia (2 arms), sponsored by Takeda. Primary endpoints: Pre-dialysis serum phosphorus levels at 12 weeks, Patient satisfaction questionnaire at 12 weeks and 3 more. Started Jan 2005; status: completed.
02
Drugs
lanthanum carbonate
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT00160121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00160121.